http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007101353-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b628ab81e049bcc77a733f92cb051c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b752708fa2b943a9fcdf53f5bc5dce06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3b761e6c07b256b24a8fbe4fb718d50 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-047 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2007-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_129e7f2610ab2f25be1d629e705095e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c640163c00d5d99b436d3a89f09c3206 |
| publicationDate | 2007-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2007101353-A1 |
| titleOfInvention | A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation |
| abstract | The invention provides formulations, dosage forms, and treatments comprising cyclohexane polyalcohol compounds that provide beneficial pharmacokinetic profiles in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence. In aspects of the invention, a dosage form is provided comprising an amount of a cyclohexane polyalcohol compound suitable for administration to a subject to provide a therapeutically effective concentration of the compound in plasma, brain and/or cerebral spinal fluid and a pharmaceutically acceptable carrier, diluent or excipient. The formulation can be administered in a dose of 500, 1000, 2000, 3500, 5000 or 7000 mg of cyclohexane polyalcohol compound to achieve a mean plasma concentration profile having a mean AUC0-INF in µ.h/mL of, respectively, 43±20%, 130±20%, 215±20%, 467±20%, 507±20% or 885±20%, and having a mean Cmax in µmL of, respectively, 5.8±20%, 17±20%, 33±20%, 75±20%, 110±20% or 155±20%. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008034244-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102007030695-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9833420-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012173808-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008061373-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8859628-B2 |
| priorityDate | 2006-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 780.